chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: Soreness of Arm; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Soreness of Arm) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No medical history information was reported.     On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced INJECTION SITE PAIN (Soreness of Arm). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, INJECTION SITE PAIN (Soreness of Arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Jan-2021 and was forwarded to Moderna on 23-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (Soreness of Arm) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No medical history information was reported.     On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced INJECTION SITE PAIN (Soreness of Arm). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, INJECTION SITE PAIN (Soreness of Arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: Positive covid-19 quick test 1 week after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Positive covid-19 quick test 1 week after 1st dose) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included INSULIN PORCINE (INSULINA ACTRAPID), ATORVASTATIN and LEVOTHYROXINE SODIUM (LEVOTIROXIN) for an unknown indication.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced COVID-19 (Positive covid-19 quick test 1 week after 1st dose). At the time of the report, COVID-19 (Positive covid-19 quick test 1 week after 1st dose) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment details was reported.   Reporter did not allow further contact
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: rash at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at the injection site) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     NO medical history information was reported.     On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE RASH (rash at the injection site). At the time of the report, VACCINATION SITE RASH (rash at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Jan-2021 and was forwarded to Moderna on 22-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (rash at the injection site) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     NO medical history information was reported.     On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE RASH (rash at the injection site). At the time of the report, VACCINATION SITE RASH (rash at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  No treatment details were reported.
Sex: M
Vaccine: COVID19
Symptoms: Adverse drug reaction
Clinical narrative: had a reaction; This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE DRUG REACTION (had a reaction) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     NO medical history information was reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 1. On an unknown date, the patient experienced ADVERSE DRUG REACTION (had a reaction). At the time of the report, ADVERSE DRUG REACTION (had a reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Jan-2021 and was forwarded to Moderna on 23-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE DRUG REACTION (had a reaction) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     NO medical history information was reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 1. On an unknown date, the patient experienced ADVERSE DRUG REACTION (had a reaction). At the time of the report, ADVERSE DRUG REACTION (had a reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided.  No treatment details were reported.
Sex: F
Vaccine: COVID19
Symptoms: Rash, Vaccination site rash
Clinical narrative: rash shoulder right; Rash on top of both legs (thigh); rash shoulder left; Rash forearm; This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash shoulder left), RASH (rash shoulder right), RASH (Rash on top of both legs (thigh)) and VACCINATION SITE RASH (Rash forearm) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     No medical history information was reported.     On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Dec-2020, the patient experienced VACCINATION SITE RASH (Rash forearm). On 31-Dec-2020, the patient experienced RASH (rash shoulder left). On 01-Jan-2021, the patient experienced RASH (Rash on top of both legs (thigh)). On 21-Jan-2021, the patient experienced RASH (rash shoulder right). The patient was treated with LORATADINE (CLARITIN [LORATADINE]) at an unspecified dose and frequency and HYDROCORTISONE at a dose of Cream. On 21-Jan-2021, RASH (rash shoulder left), RASH (rash shoulder right), RASH (Rash on top of both legs (thigh)) and VACCINATION SITE RASH (Rash forearm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Jan-2021 and was forwarded to Moderna on 23-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash shoulder left), RASH (rash shoulder right), RASH (Rash on top of both legs (thigh)) and VACCINATION SITE RASH (Rash forearm) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     No medical history information was reported.     On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Dec-2020, the patient experienced VACCINATION SITE RASH (Rash forearm). On 31-Dec-2020, the patient experienced RASH (rash shoulder left). On 01-Jan-2021, the patient experienced RASH (Rash on top of both legs (thigh)). On 21-Jan-2021, the patient experienced RASH (rash shoulder right). The patient was treated with LORATADINE (CLARITIN [LORATADINE]) at an unspecified dose and frequency and HYDROCORTISONE at a dose of Cream. On 21-Jan-2021, RASH (rash shoulder left), RASH (rash shoulder right), RASH (Rash on top of both legs (thigh)) and VACCINATION SITE RASH (Rash forearm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported.
Sex: F
Vaccine: COVID19
Symptoms: Breast mass
Clinical narrative: a lump in her breast for 3 days after getting the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of BREAST MASS (a lump in her breast for 3 days after getting the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BREAST MASS (a lump in her breast for 3 days after getting the vaccine). At the time of the report, BREAST MASS (a lump in her breast for 3 days after getting the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Jan-2021 and was forwarded to Moderna on 22-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of BREAST MASS (a lump in her breast for 3 days after getting the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BREAST MASS (a lump in her breast for 3 days after getting the vaccine). At the time of the report, BREAST MASS (a lump in her breast for 3 days after getting the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported.
Sex: F
Vaccine: COVID19
Symptoms: Skin reaction
Clinical narrative: Delayed reaction; This spontaneous case was reported by a consumer and describes the occurrence of SKIN REACTION (Delayed reaction) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SKIN REACTION (Delayed reaction). At the time of the report, SKIN REACTION (Delayed reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported.    This case was linked to MOD-2021-012462 (Patient Link). This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 25-Jan-2021 and was forwarded to Moderna on 25-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of SKIN REACTION (Delayed reaction) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SKIN REACTION (Delayed reaction). At the time of the report, SKIN REACTION (Delayed reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported.    This case was linked to MOD-2021-012462 (Patient Link).
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Nasal congestion
Clinical narrative: nasal congestion; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (nasal congestion) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included Acid reflux (esophageal) since an unknown date, Anxiety since an unknown date, Cholesterol since an unknown date, Hypertension since an unknown date and Pain since an unknown date. Concomitant products included OMEPRAZOLE for Acid reflux (esophageal), GABAPENTIN for Anxiety, SIMVASTATIN for Cholesterol, ATENOLOL and LISINOPRIL for Hypertension, NAPROXEN SODIUM (NAPROXENE [NAPROXEN SODIUM]) for Pain, VITAMIN B COMPLEX for an unknown indication.    On 11-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NASAL CONGESTION (nasal congestion). At the time of the report, NASAL CONGESTION (nasal congestion) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Jan-2021 and was forwarded to Moderna on 23-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (nasal congestion) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included Acid reflux (esophageal) since an unknown date, Anxiety since an unknown date, Cholesterol since an unknown date, Hypertension since an unknown date and Pain since an unknown date. Concomitant products included OMEPRAZOLE for Acid reflux (esophageal), GABAPENTIN for Anxiety, SIMVASTATIN for Cholesterol, ATENOLOL and LISINOPRIL for Hypertension, NAPROXEN SODIUM (NAPROXENE [NAPROXEN SODIUM]) for Pain, VITAMIN B COMPLEX for an unknown indication.    On 11-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NASAL CONGESTION (nasal congestion). At the time of the report, NASAL CONGESTION (nasal congestion) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: COVID-19 positive quick test; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of COVID-19 (COVID-19 positive quick test) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced COVID-19 (COVID-19 positive quick test). At the time of the report, COVID-19 (COVID-19 positive quick test) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Jan-2021, SARS-CoV-2 test positive: positive quick test.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  Treatment information was not provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Jan-2021 and was forwarded to Moderna on 22-Jan-2021.    This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of COVID-19 (COVID-19 positive quick test) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced COVID-19 (COVID-19 positive quick test). At the time of the report, COVID-19 (COVID-19 positive quick test) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Jan-2021, SARS-CoV-2 test positive: positive quick test.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided.  Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: arm is sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (arm is sore) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. PZ9112OA) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE PAIN (arm is sore). At the time of the report, VACCINATION SITE PAIN (arm is sore) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications are not provided.   Treatment information not provided.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy
Clinical narrative: pregnant;received Moderna COVID-19 Vaccine; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (pregnant;received Moderna COVID-19 Vaccine) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for Covid-19 vaccination.     No Medical History information was reported.    On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. The patient's last menstrual period was on 17-Aug-2020 and the estimated date of delivery was 31-May-2021. On 06-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (pregnant;received Moderna COVID-19 Vaccine). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-fourth week of the pregnancy.  On 06-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (pregnant;received Moderna COVID-19 Vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant  medication information was provided by the reporter.  No treatment information was provided by the reporter.
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Peripheral swelling
Clinical narrative: arm was red; swollen; This spontaneous case was reported by a consumer and describes the occurrence of   in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant information provided. Treatment included Ice
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Nausea
Clinical narrative: Has not eaten; Felt nauseous; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Felt nauseous) and DECREASED APPETITE (Has not eaten) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     Concurrent medical conditions included Anxiety. Concomitant products included HYOSCINE HYDROBROMIDE (SCOPOLAMINE PCH), BETHANECHOL, ALPRAZOLAM (XANAX) and ESCITALOPRAM OXALATE (LEXAPRO).    On 21-Jan-2021 at 1:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021, the patient experienced NAUSEA (Felt nauseous). On an unknown date, the patient experienced DECREASED APPETITE (Has not eaten). At the time of the report, NAUSEA (Felt nauseous) and DECREASED APPETITE (Has not eaten) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No treatment information provided.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pyrexia, Vaccination site pain
Clinical narrative: fever; chills; feeling tired; muscle soreness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (muscle soreness at the injection site), PYREXIA (fever), CHILLS (chills) and FATIGUE (feeling tired) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024L20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy and Blood pressure.    On 21-Jan-2021 at 9:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Jan-2021 at 12:00 PM, the patient experienced VACCINATION SITE PAIN (muscle soreness at the injection site). On 22-Jan-2021 at 2:00 AM, the patient experienced PYREXIA (fever), CHILLS (chills) and FATIGUE (feeling tired). On 22-Jan-2021, PYREXIA (fever) had resolved. At the time of the report, VACCINATION SITE PAIN (muscle soreness at the injection site), CHILLS (chills) and FATIGUE (feeling tired) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant information provided. Treatment included For the symptoms he took 2 sets of Tylenol on 21Jan2021 at noon, 2 sets of Tylenol that same day on the evening, and 2 sets of Tylenol on 22Jan2021 at 2am. General medications: for his allergies and for his blood pressure. FM 22Jan2021
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site cellulitis, Injection site erythema, Injection site mass, Injection site rash, Pain in extremity
Clinical narrative: injection site cellulitis; injection site swollen; injection site red, hot; rash at injection site; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE CELLULITIS (injection site cellulitis), PAIN IN EXTREMITY (Sore arm), INJECTION SITE MASS (injection site swollen), INJECTION SITE ERYTHEMA (injection site red, hot) and INJECTION SITE RASH (rash at injection site) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced PAIN IN EXTREMITY (Sore arm). On 15-Jan-2021, the patient experienced INJECTION SITE MASS (injection site swollen), INJECTION SITE ERYTHEMA (injection site red, hot) and INJECTION SITE RASH (rash at injection site). On an unknown date, the patient experienced INJECTION SITE CELLULITIS (injection site cellulitis). At the time of the report, INJECTION SITE CELLULITIS (injection site cellulitis), PAIN IN EXTREMITY (Sore arm), INJECTION SITE MASS (injection site swollen), INJECTION SITE ERYTHEMA (injection site red, hot) and INJECTION SITE RASH (rash at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.   Treatment for the event included Keflex (cefalexin monohydrate) and doxycycline.    This case was linked to US-MODERNATX, INC.-MOD-2021-013959 (E2B Linked Report). This case was linked to MOD-2021-012383 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-013959:same reportrer, different patient
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Vaccination site reaction
Clinical narrative: localize reaction; itching; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE REACTION (localize reaction) and PRURITUS (itching) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     Concomitant products included LISINOPRIL.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced VACCINATION SITE REACTION (localize reaction) and PRURITUS (itching). At the time of the report, VACCINATION SITE REACTION (localize reaction) and PRURITUS (itching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information provided.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Injection site discomfort, Vaccination site erythema, Vaccination site pain, Vaccination site pruritus
Clinical narrative: Some discomfort in the arm at injection site; * days later arm itchy,red and swollen; arm got red; arm slightly swollen; achy; headachy; This spontaneous case was reported by an other and describes the occurrence of INJECTION SITE DISCOMFORT (Some discomfort in the arm at injection site), VACCINATION SITE PRURITUS (* days later arm itchy,red and swollen), VACCINATION SITE ERYTHEMA (arm got red), VACCINATION SITE SWELLING (arm slightly swollen) and VACCINATION SITE PAIN (achy) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no adverse event reported). Concomitant products included LISINOPRIL, HYDROCHLOROTHIAZIDE and OMEPRAZOLE for an unknown indication.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Jan-2021, the patient experienced VACCINATION SITE PAIN (achy) and HEADACHE (headachy). On 21-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (* days later arm itchy,red and swollen), VACCINATION SITE ERYTHEMA (arm got red) and VACCINATION SITE SWELLING (arm slightly swollen). On an unknown date, the patient experienced INJECTION SITE DISCOMFORT (Some discomfort in the arm at injection site). On 24-Jan-2021, VACCINATION SITE PRURITUS (* days later arm itchy,red and swollen) and VACCINATION SITE ERYTHEMA (arm got red) outcome was unknown, VACCINATION SITE SWELLING (arm slightly swollen) had resolved. At the time of the report, INJECTION SITE DISCOMFORT (Some discomfort in the arm at injection site), VACCINATION SITE PAIN (achy) and HEADACHE (headachy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant information provided. No treatment information provided.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: Some discomfort in the arm at injection site; * days later arm itchy,red and swollen; arm got red; arm slightly swollen; achy; headachy; This spontaneous case was reported by an other and describes the occurrence of INJECTION SITE DISCOMFORT (Some discomfort in the arm at injection site), VACCINATION SITE PRURITUS (* days later arm itchy,red and swollen), VACCINATION SITE ERYTHEMA (arm got red), VACCINATION SITE SWELLING (arm slightly swollen) and VACCINATION SITE PAIN (achy) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no adverse event reported). Concomitant products included LISINOPRIL, HYDROCHLOROTHIAZIDE and OMEPRAZOLE for an unknown indication.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Jan-2021, the patient experienced VACCINATION SITE PAIN (achy) and HEADACHE (headachy). On 21-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (* days later arm itchy,red and swollen), VACCINATION SITE ERYTHEMA (arm got red) and VACCINATION SITE SWELLING (arm slightly swollen). On an unknown date, the patient experienced INJECTION SITE DISCOMFORT (Some discomfort in the arm at injection site). On 24-Jan-2021, VACCINATION SITE PRURITUS (* days later arm itchy,red and swollen) and VACCINATION SITE ERYTHEMA (arm got red) outcome was unknown, VACCINATION SITE SWELLING (arm slightly swollen) had resolved. At the time of the report, INJECTION SITE DISCOMFORT (Some discomfort in the arm at injection site), VACCINATION SITE PAIN (achy) and HEADACHE (headachy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant information provided. No treatment information provided.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus
Clinical narrative: I experienced itching at injection site; I experienced redness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (I experienced itching at injection site) and VACCINATION SITE PRURITUS (I experienced redness at injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (I experienced itching at injection site) and VACCINATION SITE PRURITUS (I experienced redness at injection site). At the time of the report, VACCINATION SITE ERYTHEMA (I experienced itching at injection site) and VACCINATION SITE PRURITUS (I experienced redness at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The relevant concomitant medications were also not provided.  No treatment information was provided.
Sex: M
Vaccine: COVID19
Symptoms: Skin reaction
Clinical narrative: had the same reaction; This spontaneous case was reported by a consumer and describes the occurrence of SKIN REACTION (had the same reaction) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SKIN REACTION (had the same reaction). At the time of the report, SKIN REACTION (had the same reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy
Clinical narrative: Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 027L20A) for COVID-19 vaccination.     Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] and ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 06-Jun-2021. On 05-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). On 05-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.
Sex: M
Vaccine: COVID19
Symptoms: Malaise, Pain in extremity
Clinical narrative: sore arm; malaise; This spontaneous case was reported by a consumer and describes the occurrence of   in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Injection site induration, Injection site inflammation, Injection site pruritus
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of injection site pruritus (itching), injection site induration (hardening) and injection site inflammation in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On Jan 14, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On Jan 21, 2021, patient experienced injection site pruritus (itching), injection site induration (hardening) and injection site inflammation. At the time of the report, injection site pruritus (itching), injection site induration (hardening) and injection site inflammation outcome was unknown/not provided. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. Concomitant product use and treatment information not provided.
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash vesicular, Urticaria
Clinical narrative: really itchy; saw a couple of them on my thighs, quads; big welts on the outside of my hands, going up to my elbows on both my arms, and a couple of them on my thighs, quads; Blisters; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (saw a couple of them on my thighs, quads) and PRURITUS (really itchy) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced URTICARIA (saw a couple of them on my thighs, quads). On an unknown date, the patient experienced PRURITUS (really itchy). At the time of the report, URTICARIA (saw a couple of them on my thighs, quads) and PRURITUS (really itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication provided.   Treatment for the event was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Injection site irritation, Injection site pruritus, Injection site rash
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of injection site irritation ("hive-like" bump a couple of inches below the injection site) and injection site rash (injection site rash formed a 6-inch diameter around the injection site) in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. The patient's past medical history included no adverse event. On an unknown date, patient received dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced injection site irritation ("hive-like" bump a couple of inches below the injection site) and injection site rash (injection site rash formed a 6-inch diameter around the injection site). At the time of the report, injection site irritation ("hive-like" bump a couple of inches below the injection site) and injection site rash (injection site rash formed a 6-inch diameter around the injection site): resolved. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. No concomitant information and treatment information provided.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Headache, Nausea
Clinical narrative: nausea and headache on and off; nausea and headache on and off; nagging headache; Increased Morning blood pressure 147 to 150mmHg; nausea; This spontaneous case was reported by a patient and describes the occurrence of NAUSEA (nausea), HEADACHE (nagging headache), NAUSEA (nausea and headache on and off) and HEADACHE (nausea and headache on and off) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ESOMEPRAZOLE SODIUM (NEXIUM [ESOMEPRAZOLE SODIUM]) for Acid reflux (oesophageal).    The patient's past medical history included Aortic aneurysm enlargement and Liver transplant (post liver transplant 15yrs ago medications used during liver transplant- cyclosporine 125mg daily Ursidiol). Concurrent medical conditions included Hypertension (Drugs for HBP-Metoprolol, Losartan,,Amlodipine taking). Concomitant products included METOPROLOL, LOSARTAN and AMLODIPINE for Hypertension, CYCLOSPORINE and URSODIOL for Liver transplant.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ESOMEPRAZOLE SODIUM (NEXIUM [ESOMEPRAZOLE SODIUM]) (unknown route) at an unspecified dose. On 08-Jan-2021, the patient experienced NAUSEA (nausea). On 09-Jan-2021, the patient experienced HEADACHE (nagging headache). On 10-Jan-2021, the patient experienced NAUSEA (nausea and headache on and off) and HEADACHE (nausea and headache on and off). At the time of the report, NAUSEA (nausea), HEADACHE (nagging headache), NAUSEA (nausea and headache on and off) and HEADACHE (nausea and headache on and off) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information provided.
Sex: M
Vaccine: COVID19
Symptoms: Asthenia
Clinical narrative: Weakness; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weakness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Gout. Concomitant products included CORTISONE for Gout.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (Weakness). At the time of the report, ASTHENIA (Weakness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication was not reported.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: outcome updated
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Heart rate increased, Nausea, Pyrexia
Clinical narrative: Chills; Fever of 101; Nausea; Extreme thrist; heart rate increased to 80bpm; Headache; Injection site soreness; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Headache), VACCINATION SITE PAIN (Injection site soreness), CHILLS (Chills), PYREXIA (Fever of 101) and NAUSEA (Nausea) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029KZ0A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no reported medical history).    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced HEADACHE (Headache) and VACCINATION SITE PAIN (Injection site soreness). On 21-Jan-2021, the patient experienced CHILLS (Chills), PYREXIA (Fever of 101), NAUSEA (Nausea), THIRST (Extreme thrist) and HEART RATE INCREASED (heart rate increased to 80bpm). At the time of the report, HEADACHE (Headache), VACCINATION SITE PAIN (Injection site soreness), CHILLS (Chills), PYREXIA (Fever of 101), NAUSEA (Nausea), THIRST (Extreme thrist) and HEART RATE INCREASED (heart rate increased to 80bpm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant information - Medication to slow her heart rate No treatment information provided.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Thirst, Vaccination site pain
Clinical narrative: Chills; Fever of 101; Nausea; Extreme thrist; heart rate increased to 80bpm; Headache; Injection site soreness; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Headache), VACCINATION SITE PAIN (Injection site soreness), CHILLS (Chills), PYREXIA (Fever of 101) and NAUSEA (Nausea) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029KZ0A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no reported medical history).    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced HEADACHE (Headache) and VACCINATION SITE PAIN (Injection site soreness). On 21-Jan-2021, the patient experienced CHILLS (Chills), PYREXIA (Fever of 101), NAUSEA (Nausea), THIRST (Extreme thrist) and HEART RATE INCREASED (heart rate increased to 80bpm). At the time of the report, HEADACHE (Headache), VACCINATION SITE PAIN (Injection site soreness), CHILLS (Chills), PYREXIA (Fever of 101), NAUSEA (Nausea), THIRST (Extreme thrist) and HEART RATE INCREASED (heart rate increased to 80bpm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant information - Medication to slow her heart rate No treatment information provided.
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Pain, Pyrexia
Clinical narrative: Low Grade Fever; Headache; Body Ache; Fatigue; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of   in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ACETAMINOPHEN for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Sex: M
Vaccine: COVID19
Symptoms: Chills, Dizziness, Limb discomfort, Pain
Clinical narrative: sore arm; pain; chills; lightheaded; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (sore arm), PAIN (pain), CHILLS (chills) and DIZZINESS (lightheaded) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030120A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 21-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced LIMB DISCOMFORT (sore arm), PAIN (pain), CHILLS (chills) and DIZZINESS (lightheaded). At the time of the report, LIMB DISCOMFORT (sore arm), PAIN (pain), CHILLS (chills) and DIZZINESS (lightheaded) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cold sweat, Feeling hot, Headache, Hypertension
Clinical narrative: Cold sweats; Headache; Hard lymph node; Hot to touch lymph nodes; Fever; Chills; Racing heart; High blood pressure; Pain at injection site; Pain at axiillary lymph node; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), CHILLS (Chills), PALPITATIONS (Racing heart), HYPERTENSION (High blood pressure) and VACCINATION SITE PAIN (Pain at injection site) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.     On 19-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced PYREXIA (Fever), CHILLS (Chills), PALPITATIONS (Racing heart), HYPERTENSION (High blood pressure), VACCINATION SITE PAIN (Pain at injection site) and LYMPH NODE PAIN (Pain at axiillary lymph node). On 21-Jan-2021, the patient experienced LYMPHADENOPATHY (Hard lymph node) and FEELING HOT (Hot to touch lymph nodes). On an unknown date, the patient experienced COLD SWEAT (Cold sweats) and HEADACHE (Headache). On 22-Jan-2021, LYMPHADENOPATHY (Hard lymph node) and FEELING HOT (Hot to touch lymph nodes) outcome was unknown. At the time of the report, PYREXIA (Fever), CHILLS (Chills), PALPITATIONS (Racing heart), HYPERTENSION (High blood pressure), VACCINATION SITE PAIN (Pain at injection site), LYMPH NODE PAIN (Pain at axiillary lymph node), COLD SWEAT (Cold sweats) and HEADACHE (Headache) outcome was unknown.